Evaluating APTT/Fibrinogen Ratio for Diagnosing Pulmonary Embolism
The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism
Nanfang Hospital, Southern Medical University · NCT06192199
This study is testing if the APTT/fibrinogen ratio can help doctors better diagnose pulmonary embolism in patients who might have it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University (other) |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06192199 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the diagnostic value of the APTT/fibrinogen ratio in patients suspected of having acute pulmonary embolism. Conducted at Nanyang Hospital of Southern Medical University, the study will collect and analyze various clinical data, including imaging results and laboratory tests, to differentiate between patients with and without pulmonary embolism. The study will also follow up on the APTT/fibrinogen ratio after anticoagulation treatment in the pulmonary embolism group to evaluate its clinical relevance.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are suspected of having pulmonary embolism and are undergoing CTPA examination.
Not a fit: Patients with gastrointestinal bleeding, severe trauma, or those on regular anticoagulant therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of diagnosing pulmonary embolism, leading to timely and appropriate treatment for patients.
How similar studies have performed: While the specific approach of using the APTT/fibrinogen ratio is novel, similar studies have explored various biomarkers for diagnosing pulmonary embolism with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Voluntary signing of informed consent form; 2. When signing the informed consent form, the age is equal to or greater than 18 years old, regardless of gender; 3. From January 1, 2023 to December 30, 2023, the patient was diagnosed with suspected pulmonary embolism at the Southern Hospital of Southern Medical University and underwent enhanced pulmonary artery scanning examination. Exclusion Criteria: 1. Patients with gastrointestinal bleeding, severe trauma, acute coronary syndrome, severe liver disease (childC grade), and coagulation dysfunction; 2. Patients with pulmonary embolism diagnosed outside the hospital and regular anticoagulation; 3. Patients undergoing regular anticoagulant therapy such as atrial fibrillation and valve replacement; 4. Patients deemed unsuitable for participation in this study by the researchers.
Where this trial is running
Guangzhou, Guangdong
- Nanfang hospital of Southern Medical University — Guangzhou, Guangdong, China (RECRUITING)
Study contacts
- Study coordinator: Xintong Huang
- Email: 1556807596@qq.com
- Phone: 8619355230761
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Pulmonary Embolism